Emla-Cream as Pain Relief During Pneumococcal Vaccination

Not Applicable

Completed

• Conditions: Children; Pain
• Interventions: Drug: Emla-cream; Drug: Miniderm cream

• Registration Number: NCT01802086
• Lead Sponsor: Beatrice Olsson Duse

Brief Summary

The aim of this intervention study is to compare the efficacy of Emla cream as a pain relief or no pain relief in connection to the first pneumococcal vaccination at the age of three months in Child health care.

Primary objective

1.Leads Emla cream as pain relief to children in connection with pneumococcal vaccination at the age of three months to lower pain scores in the use of FLACC as a pain measurement instrument?

Detailed Description

The aim of this intervention study is to compare the efficacy of Emla cream as a pain relief or no pain relief in connection to the first pneumococcal vaccination at the age of three months in Child health care.

Primary objective

1. Leads Emla cream as pain relief to children in connection with pneumococcal vaccination at the age of three months to lower pain scores in the use of FLACC as a pain measurement instrument?

Secondary objectives

2. Leads Emla cream as pain relief in connection with pneumococcal vaccination to any difference in the child's heart rate response and saturation?

3. Leads Emla cream as pain relief that it takes longer before the baby starts crying and does the child cry for a shorter time in connection with vaccination?

Method: The study is randomised and singleblind. The study involves 72 children who are 3 months old. 36 children will receive Emla-cream and 36 children will receive placebo-cream.

This study will lead to new knowledge about Emla cream and pneumococcal vaccination. The study will give new knowledge how painful pneumococcal vaccination is for the children. If the study shows that Emla cream don´t give enough pain relief during pneumococcal vaccination more studies should be done with other pain relief.

Study Timeline

• Study First Submitted: 2012-10-31
• Study First Submitted QC: 2013-02-27
• Study First Posted: 2013-03-01
• Study Start: 2013-05
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-02
• Last Update Posted: 2021-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Healthy children, born vaginally or by cesarean section after 37 weeks of gestation, who were not admitted to the neonatal unit. Children should only have been with the PKU testing performed routinely at the hospital.

Exclusion Criteria

• Baby delivered by vacuum extraction or forceps. Children born before gestational week 37. Children in neonatal care and subjected to other testing than PKU. Shoulder dystocia. Children susceptible to methaemoglobinaemia in glucose 6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia. Children with atopic dermatitis.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Emla-cream	Emla-cream	Dose: 1 g Emla-cream, 1 hour.
Miniderm cream	Miniderm cream	Dose: 1 g Miniderm-cream, 1 hour.

Primary Outcome Measures

Name	Time	Method
Measuring the effect of Emla cream on pain perception during pneumococcal vaccination measured with FLACC.	one year	Score of FLACC-points.

Secondary Outcome Measures

Name	Time	Method
Pain perception measured with parental perceived VAS, cry-time and pysiological parametical.	one year	VAS-units; Cry-time: how long does it takes until the baby starts to cry and for how long time is the baby crying.; Heartbeat/minute; Saturation/minute

Trial Locations

Locations (1)

Healthcare center Mariefred/Strängnäs; 🇸🇪 Mariefred, Sweden